TDC
CTMX icon

Thompson Davis & Co’s CytomX Therapeutics CTMX Stock Holding History

Thompson Davis & Co’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$2K Hold
125
– – ﹤0.01% 658
2018
Q2 		$3K Hold
125
– – 0.01% 572
2018
Q1 		$4K Hold
125
– – 0.01% 510
2017
Q4 		$3K Buy
+125
New +$2.59K 0.01% 570

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Thompson Davis & Co's CTMX Position: Q3 2018 in Review

Thompson Davis & Co held its CytomX Therapeutics (CTMX) position steady in Q3 2018 at 125 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #658.

Thompson Davis & Co first reported a position in CTMX in Q4 2017 and has held it in 4 quarters since. The position peaked at $4K in Q1 2018. 122 funds tracked by Wall St. Rank hold CTMX as of Q3 2018.

  • Thompson Davis & Co held 125 shares of CytomX Therapeutics worth $2K as of Q3 2018.
  • Thompson Davis & Co left its CytomX Therapeutics share count unchanged in Q3 2018.
  • CytomX Therapeutics made up ﹤0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #658 holding.
  • Thompson Davis & Co first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 4 quarters since.
  • Thompson Davis & Co's CytomX Therapeutics position peaked at $4K in Q1 2018.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.